Regent Pacific Group Ltd represents values of integrity, innovation, and responsibility. As a leading company, it focuses on strategic investments in the healthcare sector. Regent Pacific Group Ltd is committed to delivering high-quality healthcare products and services, while upholding ethical standards. With a forward-thinking corporate philosophy, the company actively seeks opportunities to improve healthcare accessibility and enhance patient care. Regent Pacific Group Ltd's dedication to excellence and its emphasis on social responsibility make it a trusted partner in the healthcare industry.

Regent Pacific Group Ltd is primarily present in Hong Kong and the People's Republic of China.

Regent Pacific Group Ltd has achieved several significant milestones throughout its history. Notably, the company successfully completed its initial public offering (IPO) and got listed on the main board of the Hong Kong Stock Exchange in [year]. It has also expanded its portfolio through strategic acquisitions and partnerships in various industries, including healthcare and biotechnology. Regent Pacific Group Ltd has demonstrated consistent growth and profitability, exemplified by its strong financial performance and increased market capitalization over time. With its continued focus on innovation and investment opportunities, the company strives to achieve further milestones and deliver value to its shareholders.

Regent Pacific Group Ltd is a leading investment firm with a rich history and background. Established in [year], the company has been actively involved in various industries, including healthcare, biotechnology, and investment sectors. Regent Pacific Group Ltd focuses on identifying promising investment opportunities and delivering value to its shareholders. With a diverse portfolio of investments and an experienced management team, the company strives to achieve long-term growth and sustainable business performance. Regent Pacific Group Ltd is dedicated to maintaining its reputation as a trusted investment partner and continues to enhance shareholder value through strategic investments and sound business practices.

The main competitors of Regent Pacific Group Ltd in the market are other pharmaceutical companies, such as China Grand Pharmaceutical and Healthcare Holdings Limited, CSPC Pharmaceutical Group Limited, and Sihuan Pharmaceutical Holdings Group Ltd.

Regent Pacific Group Ltd is primarily active in the healthcare and pharmaceutical industries.

Regent Pacific Group Ltd operates as a diversified investment holding company. The company's primary focus lies in acquiring and investing in businesses within the healthcare, nutrition, and specialty pharmaceutical sectors. Regent Pacific Group aims to identify innovative healthcare companies and support them in expanding their presence globally. With a strategic approach, the company seeks opportunities for growth, considering both organic expansion and potential collaborations. Regent Pacific Group Ltd's business model revolves around actively managing a diverse portfolio of investments, capitalizing on the evolving trends and demands in the healthcare industry.

Az KGV a Regent Pacific Group esetében jelenleg nem számítható ki.

A Regent Pacific Group számára az aktuális KUV nem számítható ki.

Az AlleAktien Minőségi Score Regent Pacific Group esetében 3/10.

A Regent Pacific Group esetében jelenleg nem számítható ki az árbevétel.

A nyereséget jelenleg nem lehet kiszámítani a Regent Pacific Group számára.

Regent Pacific Group Ltd is a Hong Kong-based company specializing in investments in the healthcare and biotechnology sectors. The company's business model is to invest in promising companies in these sectors to promote their long-term growth and diversify its portfolio. One important division of Regent Pacific Group Ltd is its investment sector, where the company invests in promising companies in the biotechnology, healthcare, and medical technology fields that are in the clinical development phase. This includes companies like RMedLabs, Innovent, BioLineRx, and ARX Oncology. Through its investments in these companies, Regent Pacific Group Ltd aims to drive their growth and increase its own profits. Another segment of the business model is the Pharma Solutions division, which the company focuses on as part of its growth strategy. Here, it offers various products and services to pharmaceutical and manufacturing companies, including drug approval, clinical development, manufacturing, and marketing. Regent Pacific provides pharmaceutical raw materials, finished products, and medical devices in the China and Asia regions. Another significant business area for Regent Pacific Group Ltd is the distribution and marketing support of pharmaceutical products in Asia and North America. The company has established long-term relationships with key players in the healthcare industry such as hospitals, health authorities, and medical associations, enabling it to market products effectively. As part of its extensive business model, Regent Pacific also engages in research and development of new products in the biotechnology and healthcare sectors. The company focuses its research on developing drugs for the treatment of serious diseases like cancer and diabetes, as well as investigating new therapy forms like regenerative medicine. Overall, Regent Pacific Group Ltd offers a wide range of products and services, giving it a unique position in the market. The company's business model is typically characterized by stability and low volatility due to its various divisions. Additionally, the increasing demand and growing need for medical advancements in Asia and North America make it an interesting and attractive market.

A(z) Regent Pacific Group évente alkalommal oszt ki 0 USD összegű osztalékot.

A Regent Pacific Group esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Regent Pacific Group ISIN kódja: KYG7478U1206.

Az Regent Pacific Group tőzsdei rövidítése 575.HK.

Az elmúlt 12 hónapban a(z) Regent Pacific Group osztalékot fizetett 1,30 USD összegben. Ez körülbelül 2525,85 % osztalékhozamnak felel meg. A következő 12 hóban a(z) Regent Pacific Group várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Regent Pacific Group jelenlegi osztalékhozama 2525,85 %.

A(z) Regent Pacific Group negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: július, február, február, március.

A Regent Pacific Group az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Regent Pacific Group a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Regent Pacific Group által 2013. 03. 15.-án/én fizetett 0,13 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2013. 02. 08.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2013. 03. 15. időpontban történt.

2023 évben a Regent Pacific Group 0 USD összegű osztalékot fizetett ki.

Az Regent Pacific Group osztalékait USD fizeti ki.